Harvey Jones has spotted signs of life in the GSK share price. Which is a relief after its recent troubles, so can the FTSE ...

AstraZeneca is making a $1bn investment for the long term, but what lies in store for investors over the next 12 months? Here ...

("GSK" or the "Company") (NYSE ... Provide specific products and services to you, such as portfolio management or data aggregation. Develop and improve features of our offerings.

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

“Emma led the executive team and the wider organisation to deliver continued, improved operating performance in 2024, with GSK’s reshaped product portfolio demonstrating both strength and ...

Provide specific products and services to you, such as portfolio management or data aggregation. Develop and improve features of our offerings. Gear advertisements and other marketing efforts ...

The four-pronged strategy begins with the acquisition of GSK's oncology portfolio, which includes all of its marketed products and late-stage candidates, for $14.5 billion, with a further $1.5 ...

With these trends in view, let’s look at the 7 most undervalued biotech stocks to invest in.

Regardless of where the markets are headed, investors may want to own companies that offer some sense of certainty in terms ...

Most of this spent is out of the pocket. By providing a big portfolio of 140 products with a relative low price, GSK is winning the game of "volume" in the market. This large portfolio also gives ...

Innoviva's strong balance sheet and stable royalty income from GlaxoSmithKline provide a ... with significant growth in product sales, notably GIAPREZA and XACDURO. Key assets like Zevtera ...